博瑞医药：子公司BGM0504片临床试验获批

Core Viewpoint - The company announced that its wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of BGM0504 tablets in overweight/obese adult patients [1] Group 1 - The approval is specifically for conducting clinical trials on BGM0504 tablets [1] - The target patient group for the trials is adults who are overweight or obese [1]